Champion Pain Care (CPAI) 10-K 29 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014
Document and Entity Information:
Entity Registrant Name	Champion Pain Care Corp
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Central Index Key	1469284
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding	46,888,500
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Public Float		$4,775,000

Champion_Pain_Care_Corporation

Champion Pain Care Corporation - Consolidated Balance Sheets (USD $)	Dec. 31, 2014		Dec. 31, 2013
Current Assets:
Cash	$343		$384
Total Current Assets	343		384
Total Assets	343		384
Current liabilities:
Accounts payable, current	83,489		81,253
Accounts payable, related parties	1,183,558		689,358
Accrued liabilities			935
Convertible debenture			47,690
Short term debt, related parties	15,250
Total Current Liabilities	1,282,297		819,236
Stockholders' Deficit:
Common stock	4,689	[1]	4,500	[1]
Additional paid-in capital	356,374		-41,537
Accumulated Deficit	-1,643,017		-781,815
Total Stockholders' Deficit	-1,281,954		-818,852
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$343		$384
[1]	$0.0001 par value; 100,000,000 shares authorized; 46,888,500 and 45,000,000 issued and outstanding.

Statement_of_Financial_Positio

Statement of Financial Position - Parenthetical (USD $)	Dec. 31, 2014	Nov. 24, 2014	Sep. 15, 2014	Dec. 31, 2013	Oct. 18, 2013
Statement of Financial Position
Common Stock, Par Value	$0.00	$0.21	$0.20	$0.00
Common Stock, Shares Authorized	100,000,000			100,000,000
Common Stock, Shares Issued	46,888,500	1,500,000	150,000	45,000,000	31,500,000
Common Stock, Shares Outstanding	46,888,500			45,000,000	13,500,000

Champion_Pain_Care_Corporation1

Champion Pain Care Corporation - Consolidated Statements of Expenses (USD $)	11 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Income Statement
Operating Expenses	($780,880)	($858,252)
Loss from operations	-780,880	-858,252
Interest expense	-935	-2,950
Net loss	($781,815)	($861,202)
Basic and Diluted Loss per common share	($0.08)	($0.02)
Basic and Diluted Weighted Average Common Shares Outstanding	9,970,060	45,222,164

Champion_Pain_Care_Corporation2

Champion Pain Care Corporation - Consolidated Statements of Cash Flows (USD $)	11 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($781,815)	($861,202)	($781,815)
Adjustments to reconcile net loss to net cash used in operating activities:
Forgiveness of accrued interest		-2,875
Stock based compensation		30,000
Changes in operating assets and liabilities:
Accounts payable, increase decrease	44,216	2,236
Accounts payable- related parties, increase decrease	689,358	814,600
Accrued expenses, increase decrease	935	2,950
Net Cash used in Operating Activities	-47,306	-15,291
Cash Flows from financing activities:
Proceeds from convertible debentures	47,690
Borrowing on debt from related party		15,250
Net cash provided by financing activities	47,790	15,250
Net change in cash	384	-41
CASH, BEGINNING OF PERIOD		384
CASH, END OF PERIOD	384	343	384
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes
Non-cash transactions:
Reverse merger adjustment	37,037
Shares issued for debt conversion		47,690
Shares issued to settle accounts payable due to related party		$320,400

Champion_Pain_Care_Corporation3

Champion Pain Care Corporation - Consolidated Statement of Changes in Stockholders' Equity (USD $)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance, Value at Dec. 31, 2012
Issuance of founder shares, Value	$3,150	($3,150)
Issuance of founder shares, Shares	31,500,000
Reverse merger adjustment, Value	1,350	-38,387		-37,037
Reverse merger adjustment, Shares	13,500,000
Net loss			-781,815	-781,815
Balance, Value at Dec. 31, 2013	4,500	-41,537	-781,815	-818,852
Balance, Shares at Dec. 31, 2013	45,000,000
Shares issued for services, Value	15	29,985		30,000
Shares issued for services, Shares	150,000
Shares issued in debt conversion, Value	24	47,676		47,700
Shares issued in debt conversion, Shares	238,500
Shares issued for accounts payable related parties, Value	150	320,250		320,400
Shares issued for accounts payable related parties, Shares	1,500,000
Net loss			-861,202	-861,202
Balance, Value at Dec. 31, 2014	$4,689	$356,374	($1,643,017)	($1,281,954)
Balance, Shares at Dec. 31, 2014	46,888,500

Note_1_Nature_of_Business_and_

Note 1 - Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
Note 1 - Nature of Business and Summary of Significant Accounting Policies	NOTE 1 – NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Business
	Champion Pain Care Corporation (the Company) was incorporated as OICco Acquisition I, Inc. under the laws of the State of Delaware on July 24, 2009. On October 31, 2014, the name of the Company was changed to Champion Pain Care Corporation.
	On October 18, 2013, Champion Care Corp. of Toronto, Canada (“Champion Toronto”), entered into a share exchange agreement with the Company, a public shell company. Pursuant to the agreement, the Company acquired all of the outstanding shares of common stock of Champion Pain Care Corp. (“CPCC”), a Nevada corporation and a wholly owned subsidiary of Champion Toronto by issuing 31,500,000 shares of its common stock to Champion Toronto in exchange for all of the CPPC issued and outstanding shares. As a result of the share exchange, Champion Toronto controlled approximately 70% of the issued and outstanding common shares of the Company resulting in a change in control. The transaction was accounted for as a reverse recapitalization transaction, as the Company qualified as a non-operating public shell company given the fact that it held nominal monetary assets, consisting of only cash at the time of merger transaction.
	The Company and CPCC hold the rights in the United States to a proprietary pain management protocol, the Champion Pain Care Protocol (the “Protocol”) which was licensed from Champion Toronto. The Company intends to acquire private medical clinics throughout the United States that specialize in the treatment and management of chronic pain and add the Protocol to the treatments already provided by acquired clinics.
	The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities
	(Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage.
	The Company has elected a fiscal year end of December 31.
	Principal of Consolidation
	Our consolidated financial statements include the accounts of Champion Pain Care Corporation, incorporated in Delaware and quoted on the OTC Markets, and Champion Pain Care Corp., incorporated in Nevada and a wholly owned subsidiary of the Company.
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Related Parties
	A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.
	Cash and Cash Equivalents
	All highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2014 and 2013.
	Income Taxes
	The Company accounts for income taxes under ASC 740 "Income Taxes".  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
	Non-Employee Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with the provision of ASC 505, “Equity Based Payments to Non-Employees” (“ASC 505”), which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest.
	Derivative Financial Instruments
	The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes option pricing model, assuming maximum value, in accordance with ASC 815-15 “Derivative and Hedging” to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	Beneficial Conversion Features
	The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.
	Fair Value of Financial Instruments
	The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
	Level 1. Observable inputs such as quoted prices in active markets;
	Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.
	The Company does not have any assets or liabilities measured at fair value on a recurring basis at December 31, 2014 and 2013. The Company did not have any fair value adjustments for assets and liabilities measured at fair value on a nonrecurring basis during the periods ended December 31, 2014 and 2013.
	Concentration of Credit Risks
	Financial instruments that potentially subject the company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp. limits. At December 31, 2014, there was no uninsured cash. Other financial instruments include notes payable and amounts due to related parties. Due to the short-term maturity of these obligations and the stated interest rates on notes payable, the carrying value of these instruments represent their fair value.
	Earnings Per Share Information
	FASB ASC 260, “Earnings Per Share” provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average common shares outstanding for the period.  Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period including stock warrants and options, using treasury stock method, and convertible preferred stock using the if-converted method. As there was a net loss for the period, basic and diluted loss per share is the same for the period from January 31, 2013 through December 31, 2013 and for the year ended December 31, 2014.
	Recent Accounting Pronouncements
	The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note_2_Going_Concern

Note 2 - Going Concern	12 Months Ended
	Dec. 31, 2014
Notes
Note 2 - Going Concern	NOTE 2 – GOING CONCERN
	The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern.  This contemplates the realization of assets and the liquidation of liabilities in the normal course of business.  Currently, the Company has minimal cash and no material assets, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern.  These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company will be dependent upon the raising of additional capital through placement of our common stock or debt financing in order to implement its business plan.  There can be no assurance that the Company will be successful in either situation in order to continue as a going concern.

Note_3_Related_Party_Payable

Note 3 - Related Party Payable	12 Months Ended
	Dec. 31, 2014
Notes
Note 3 - Related Party Payable	NOTE 3 – RELATED PARTY PAYABLE
	As of December 31, 2014, the Company has payables of $1,183,558 to related parties for unpaid consulting fees and other general and administrative expenses compared to $689,358 as of December 31, 2013. The related parties are Champion Toronto, Terrance Owen, CEO, companies owned by Terrance Owen and Nanotech Systems, Inc., a company for which Terrance Owen is the CEO and a Director.
	During the year ended December 31, 2014 a non-interest bearing loan of $15,250, payable on demand, was received by CPCC from Terrance Owen, CEO.
	On November 24, 2014, the Company issued 1,500,000 shares of its restricted common stock to Champion Toronto at a fair market value of $0.21 per share to reduce the amount payable to Champion Toronto, a related party due to having common directors with the Company, by $320,400.

Note_4_Convertible_Debentures

Note 4 - Convertible Debentures	12 Months Ended
	Dec. 31, 2014
Notes
Note 4 - Convertible Debentures	NOTE 4 – CONVERTIBLE DEBENTURES
	The Company issued two convertible debentures, in principal balance of $22,690 and $25,000 through its subsidiary, CPCC. These notes had a one year term with interest to be paid at 5% per annum. The “$22,690 note” was convertible at $0.20 per share of the Company common stock. The “$25,000 note” was to be convertible at a 25% discount to the closing market price of the Company Shares on the day the Company Shares first traded. On November 21, 2014, the Company issued 238,500 shares of its restricted common stock at a fair market value of $0.20 per share to repay both convertible debentures. In the case of the $22,690 note, a total of 113,450 shares were issued to repay the principal, 50 shares were issued to cover interest of $10 and remaining interest of $1,565 was forgiven. In the case of the $25,000 note, the accrued interest of $2,310 was forgiven.
	The Company analyzed the conversion option for beneficial conversion features consideration under ASC 470-20 “Convertible Securities with Beneficial Conversion Features” and noted none.
	The Company also analyzed the conversion option for derivative accounting under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The embedded conversion feature was measured at fair value at the date of inception and at the end of each reporting period or termination of the instrument with the change in fair value recorded to earnings. Since the Company’s common stock has had a limited trading market during the period trading commenced on July 15, 2014 to December 31, 2014 and, in addition, the Company has nominal assets and no revenue to date, the Company determined the stock is worth nil. As a result, the derivative liability is valued at zero.

Note_5_Stock_Base_Compensation

Note 5 - Stock Base Compensation	12 Months Ended
	Dec. 31, 2014
Notes
Note 5 - Stock Base Compensation	NOTE 5 – STOCK BASE COMPENSATION
	On September 15, 2014, we issued 150,000 shares of our restricted common stock at $0.20 per share in exchange for services valued at $30,000 for website management and hosting and social media activities for one year commencing on September 15, 2014.

Note_6_Reverse_Merger

Note 6 - Reverse Merger	12 Months Ended
	Dec. 31, 2014
Notes
Note 6 - Reverse Merger	NOTE 6 – REVERSE MERGER
	The authorized common stock of the Company consists of 100,000,000 shares with a $0.0001 par value.
	On October 18, 2013, Champion Care Corp. of Toronto, Canada (“Champion Toronto”), entered into a share exchange agreement with the Company, a public shell company. Pursuant to the agreement, the Company acquired all of the outstanding shares of common stock of Champion Pain Care Corp. (“CPCC”), a Nevada corporation and a wholly owned subsidiary of Champion Toronto by issuing 31,500,000 shares of its common stock to Champion Toronto in exchange for all of the CPPC issued and outstanding shares. As a result of the share exchange, Champion Toronto controlled approximately 70% of the issued and outstanding common shares of the Company resulting in a change in control.
	On October 18, 2013, the Company had 13,500,000 common shares outstanding.
	For accounting purposes, this transaction is being accounted for as a reverse merger and has been treated as a recapitalization of Champion Pain Care Corporation, with CPCC considered to be the accounting acquirer, and the financial statements of the accounting acquirer became the financial statements of the registrant. The Company did not recognize goodwill or any intangible assets in connection with the transaction. The 31,500,000 shares issued to the shareholders of CPCC in conjunction with the share exchange transaction have been presented as outstanding for all periods. The historical consolidated financial statements include the operations of the accounting acquirer for all periods presented and net assets of $(37,037) was recorded as reverse merger adjustment.

Note_7_Income_Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
Note 7 - Income Taxes	NOTE 7 – INCOME TAXES
	The Company uses the liability method, where deferred tax and liabilities are determined based on the expected future tax consequences of temporary differences between the carrying amounts of assets and liabilities for financial and income tax reporting purposes.
	From inception through December 31, 2014, the Company incurred a net loss, and, therefore, had no tax liability.
	The net deferred asset generated by the loss carry forward has been fully reserved. The cumulative net operating loss carry forward is $446,959 as of December 31, 2014 and will expire in year 2033.
	Deferred tax assets consist of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realizability.
	As of December 31, 2014 and 2013, deferred tax assets consisted of the following:
		31-Dec-14		31-Dec-13
	Net operating loss carry forward	$	151,966	31,435
	Valuation allowance		-151,966	-31,435
	Net deferred tax asset	$	0	0

Note_1_Nature_of_Business_and_1

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Nature of Business (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Nature of Business	Nature of Business
	Champion Pain Care Corporation (the Company) was incorporated as OICco Acquisition I, Inc. under the laws of the State of Delaware on July 24, 2009. On October 31, 2014, the name of the Company was changed to Champion Pain Care Corporation.
	On October 18, 2013, Champion Care Corp. of Toronto, Canada (“Champion Toronto”), entered into a share exchange agreement with the Company, a public shell company. Pursuant to the agreement, the Company acquired all of the outstanding shares of common stock of Champion Pain Care Corp. (“CPCC”), a Nevada corporation and a wholly owned subsidiary of Champion Toronto by issuing 31,500,000 shares of its common stock to Champion Toronto in exchange for all of the CPPC issued and outstanding shares. As a result of the share exchange, Champion Toronto controlled approximately 70% of the issued and outstanding common shares of the Company resulting in a change in control. The transaction was accounted for as a reverse recapitalization transaction, as the Company qualified as a non-operating public shell company given the fact that it held nominal monetary assets, consisting of only cash at the time of merger transaction.
	The Company and CPCC hold the rights in the United States to a proprietary pain management protocol, the Champion Pain Care Protocol (the “Protocol”) which was licensed from Champion Toronto. The Company intends to acquire private medical clinics throughout the United States that specialize in the treatment and management of chronic pain and add the Protocol to the treatments already provided by acquired clinics.
	The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities
	(Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage.
	The Company has elected a fiscal year end of December 31.

Note_1_Nature_of_Business_and_2

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Consolidation, Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Consolidation, Policy
	Principal of Consolidation
	Our consolidated financial statements include the accounts of Champion Pain Care Corporation, incorporated in Delaware and quoted on the OTC Markets, and Champion Pain Care Corp., incorporated in Nevada and a wholly owned subsidiary of the Company.

Note_1_Nature_of_Business_and_3

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Use of Estimates and Assumptions (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Use of Estimates and Assumptions	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Note_1_Nature_of_Business_and_4

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Related Parties (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Related Parties	Related Parties
	A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

Note_1_Nature_of_Business_and_5

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
	All highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2014 and 2013.

Note_1_Nature_of_Business_and_6

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Income Taxes	Income Taxes
	The Company accounts for income taxes under ASC 740 "Income Taxes".  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

Note_1_Nature_of_Business_and_7

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Non-employee Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Non-employee Stock-based Compensation	Non-Employee Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with the provision of ASC 505, “Equity Based Payments to Non-Employees” (“ASC 505”), which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest.

Note_1_Nature_of_Business_and_8

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Derivative Financial Instruments	Derivative Financial Instruments
	The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes option pricing model, assuming maximum value, in accordance with ASC 815-15 “Derivative and Hedging” to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Note_1_Nature_of_Business_and_9

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Beneficial Conversion Features (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Beneficial Conversion Features	Beneficial Conversion Features
	The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.

Recovered_Sheet1

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
	Level 1. Observable inputs such as quoted prices in active markets;
	Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.
	The Company does not have any assets or liabilities measured at fair value on a recurring basis at December 31, 2014 and 2013. The Company did not have any fair value adjustments for assets and liabilities measured at fair value on a nonrecurring basis during the periods ended December 31, 2014 and 2013.

Recovered_Sheet2

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Concentration of Credit Risks (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Concentration of Credit Risks	Concentration of Credit Risks
	Financial instruments that potentially subject the company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp. limits. At December 31, 2014, there was no uninsured cash. Other financial instruments include notes payable and amounts due to related parties. Due to the short-term maturity of these obligations and the stated interest rates on notes payable, the carrying value of these instruments represent their fair value.

Recovered_Sheet3

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Earnings Per Share Information (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Earnings Per Share Information	Earnings Per Share Information
	FASB ASC 260, “Earnings Per Share” provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average common shares outstanding for the period.  Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period including stock warrants and options, using treasury stock method, and convertible preferred stock using the if-converted method. As there was a net loss for the period, basic and diluted loss per share is the same for the period from January 31, 2013 through December 31, 2013 and for the year ended December 31, 2014.

Recovered_Sheet4

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note_7_Income_Taxes_Schedule_o

Note 7 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
		31-Dec-14		31-Dec-13
	Net operating loss carry forward	$	151,966	31,435
	Valuation allowance		-151,966	-31,435
	Net deferred tax asset	$	0	0

Recovered_Sheet5

Note 1 - Nature of Business and Summary of Significant Accounting Policies: Nature of Business (Details)	0 Months Ended
	Oct. 18, 2013
Details
Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration	31,500,000
Sale of Stock, Percentage of Ownership after Transaction	70.00%

Note_3_Related_Party_Payable_D

Note 3 - Related Party Payable (Details) (USD $)	Dec. 31, 2014	Nov. 24, 2014	Sep. 15, 2014	Dec. 31, 2013	Oct. 18, 2013	Sep. 30, 2014
Common Stock, Shares Issued	46,888,500	1,500,000	150,000	45,000,000	31,500,000
Common Stock, Par Value	$0.00	$0.21	$0.20	$0.00
Due to Related Parties, Current		$320,400
CPCC
Loan payable						$15,250

Note_4_Convertible_Debentures_

Note 4 - Convertible Debentures (Details) (USD $)	Dec. 31, 2014	Nov. 24, 2014	Sep. 15, 2014	Dec. 31, 2013	Oct. 18, 2013	Nov. 21, 2014	Jul. 17, 2013	Jul. 27, 2013
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Conversion Price	$0.20
Debt Instrument Conversion Percentage	25.00%
Common Stock, Shares Issued	46,888,500	1,500,000	150,000	45,000,000	31,500,000
Common Stock, Par Value	$0.00	$0.21	$0.20	$0.00
Accrued liabilities				$935
Debenture 1
Long-term Debt, Gross							22,690
Common Stock, Shares Issued						238,500
Common Stock, Par Value						$0.20
Accrued liabilities						2,310
Debenture 2
Long-term Debt, Gross								$25,000

Note_5_Stock_Base_Compensation1

Note 5 - Stock Base Compensation (Details) (USD $)	0 Months Ended	12 Months Ended
	Sep. 15, 2014	Dec. 31, 2014	Nov. 24, 2014	Dec. 31, 2013	Oct. 18, 2013
Details
Common Stock, Shares Issued	150,000	46,888,500	1,500,000	45,000,000	31,500,000
Common Stock, Par Value	$0.20	$0.00	$0.21	$0.00
Shares issued for services, Value	$30,000	$30,000

Note_6_Reverse_Merger_Details

Note 6 - Reverse Merger (Details) (USD $)	Dec. 31, 2014	Nov. 24, 2014	Sep. 15, 2014	Dec. 31, 2013	Oct. 18, 2013
Details
Common Stock, Shares Authorized	100,000,000			100,000,000
Common Stock, Par Value	$0.00	$0.21	$0.20	$0.00
Common Stock, Shares Issued	46,888,500	1,500,000	150,000	45,000,000	31,500,000
Common Stock, Shares Outstanding	46,888,500			45,000,000	13,500,000
Net Assets					($37,037)

Note_7_Income_Taxes_Details

Note 7 - Income Taxes (Details) (USD $)	Dec. 31, 2014
Details
Operating Loss Carryforwards	$446,959

Note_7_Income_Taxes_Schedule_o1

Note 7 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Deferred Tax Assets, Operating Loss Carryforwards	$151,966	$31,435
Valuation Allowance, Amount	-151,966	-31,435
Deferred Tax Assets, Net of Valuation Allowance	$0	$0